AIN
AI-Driven Gene Control

AI-Driven Gene Control

location_on UAE

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

OncoSwitch is creating the control layer for the future of genetic medicine: AI-engineered DNA switches that turn therapies on only inside cancer cells. We enable biotech and pharma to build safer, smarter, and radically more precise CGT therapies.

Highlights

  • AI-designed DNA switches for tumor-specific gene activation
  • Solving oncology’s biggest gap: precise gene-control safety
  • Early interest from UAE health authorities and oncology centers
  • Large $170B+ gene therapy and oncology market opportunity
  • Clear MPRA experimental roadmap for validating DNA switch designs

Overview

Target €1,300,000
Minimum €425,000
Investment Raised €0
Previous Rounds €0
Stage Pre-Startup/R&D
Investor Role Monthly Involvement

Ask a question
Got a question about this project?

Similar Projects